TY - JOUR
T1 - Validity of the energy-restricted Mediterranean Diet Adherence Screener
AU - PREDIMED-PLUS investigators
AU - Schröder, Helmut
AU - Zomeño, Maria Dolors
AU - Martínez-González, Miguel Angel
AU - Salas-Salvadó, Jordi
AU - Corella, Dolores
AU - Vioque, Jesús
AU - Romaguera, Dora
AU - Martínez, J. Alfredo
AU - Tinahones, Francisco J.
AU - Miranda, José López
AU - Estruch, Ramon
AU - Bueno-Cavanillas, Aurora
AU - Alonso Gómez, Angel M.
AU - Tur, Josep A.
AU - Warnberg, Julia
AU - Serra-Majem, Lluis
AU - Martín, Vicente
AU - Vázquez, Clotilde
AU - Lapetra, José
AU - Pintó, Xavier
AU - Vidal, Josep
AU - Daimiel, Lidia
AU - Gaforio, José Juan
AU - Matía-Martín, Pilar
AU - Ros, Emilio
AU - Lassale, Camille
AU - Ruiz-Canela, Miguel
AU - Babio, Nancy
AU - Sorlí, José V.
AU - García-Arellano, Ana
AU - Díaz-López, Andrés
AU - Fitó, Montserrat
AU - Castañer, Olga
N1 - Funding Information:
Dr Ros reports grants, non-financial support, and other fees from California Walnut Commission and Alexion, and non-financial support from the International Nut and Dried Fruit Council, all outside of the submitted work.
Funding Information:
Dr Estruch reported receiving grants from ISCIII and olive oil for the trial from Fundacion Patrimonio Comunal Olivarero during the conduct of the study and personal fees from Brewers of Europe, Fundación Cerveza y Salud, Interprofesional del Aceite de Oliva, Instituto Cervantes, Pernaud Richar, Fundación Dieta Mediterránea, and Wine and Culinary International Forum; also nonfinancial support from Sociedad Española de Nutrición and Fundación Bosch y Gimpera and grants from Uriach Laboratories outside the submitted work.
Funding Information:
Dr Salas-Salvadó reports serving on the board of and receiving grant support (through his institution) from the International Nut and Dried Fruit Council and the Eroski Foundation, and serving on the Executive Committee of the Instituto Danone Spain and on the Scientific Committee of the Danone International Institute. He has received research support from Patrimonio Comunal Olivarero and Borges S.A., Spain. He reports receiving consulting fees or travel expenses from Danone; Eroski Foundation, Instituto Danone—Spain, and Abbot Laboratories.
Funding Information:
The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government, ISCIII through the Fondo de Investigaci?n para la Salud (FIS), which is co-funded by the European Regional Development Fund four coordinated FIS projects led by Jordi Salas-Salvad? and Josep Vidal, including the following projects: PI13/00673, PI13/ 00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/ 00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/ 00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926; the Special Action Project entitled Implementaci?n y evaluaci?n de una intervenci?n intensiva sobre la actividad f?sica cohorte" PREDIMED-Plus grant to Jordi Salas-Salvad?; the Recercaixa grant to Jordi Salas-Salvad? (2013ACUP00194); the European Research Council Advanced Research Grant 2013?2018 (340918) granted to Miguel ?ngel Mart?nez-Gonzalez, grants from the Consejer?a de Salud de la Junta de Andaluc?a (PI0458/2013; PS0358/2016, PI0137/2018), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant and FEDER funds (CB06/03) to Josep A. Tur; the Astra Zeneca Young Investigators Award in Category of Obesity and Diabetes 2017 to Dora Romaguera; the ?FOLIUM? programme within the FUTURMed project from the Fundaci?n Instituto de Investigaci?n Sanitaria Illes Balears (financed by 2017annual plan of the sustainable tourism tax and at 50% with charge to the ESF Operational Program 2014?2020 of the Balearic Islands). JR17/00022 contract to Olga Castaner from ISCIII. CIBERobn (Centros de Investigaci?n Biomedica en Red: Obesidad y Nutrici?n), CIBEResp (Centros de Investigaci?n Biomedica en Red: Epidemiolog?a y Salud Publica) and CIBERdem (Centros de Investigaci?n Biomedica en Red: Diabetes y Enfermedades). J. Salas-Salvad? gratefully acknowledges the financial support provided by the ICREA Academia programme. None of the funding sources took part in the design, collection, analysis, or interpretation of the data; in writing the manuscript; or in the decision to submit the manuscript for publication.
Funding Information:
The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government , ISCIII through the Fondo de Investigación para la Salud (FIS) , which is co-funded by the European Regional Development Fund four coordinated FIS projects led by Jordi Salas-Salvadó and Josep Vidal, including the following projects: PI13/00673, PI13/ 00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/ 00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/ 00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926; the Special Action Project entitled Implementación y evaluación de una intervención intensiva sobre la actividad física cohorte" PREDIMED-Plus grant to Jordi Salas-Salvadó ; the Recercaixa grant to Jordi Salas-Salvadó ( 2013ACUP00194 ); the European Research Council Advanced Research Grant 2013–2018 ( 340918 ) granted to Miguel Ángel Martínez-Gonzalez , grants from the Consejería de Salud de la Junta de Andalucía ( PI0458/2013 ; PS0358/2016 , PI0137/2018 ), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant and FEDER funds (CB06/03) to Josep A. Tur; the Astra Zeneca Young Investigators Award in Category of Obesity and Diabetes 2017 to Dora Romaguera; the ‘FOLIUM’ programme within the FUTURMed project from the Fundación Instituto de Investigación Sanitaria Illes Balears (financed by 2017annual plan of the sustainable tourism tax and at 50% with charge to the ESF Operational Program 2014–2020 of the Balearic Islands). JR17/00022 contract to Olga Castaner from ISCIII. CIBERobn (Centros de Investigación Biomedica en Red: Obesidad y Nutrición), CIBEResp (Centros de Investigación Biomedica en Red: Epidemiología y Salud Publica) and CIBERdem (Centros de Investigación Biomedica en Red: Diabetes y Enfermedades). J. Salas-Salvadó gratefully acknowledges the financial support provided by the ICREA Academia programme. None of the funding sources took part in the design, collection, analysis, or interpretation of the data; in writing the manuscript; or in the decision to submit the manuscript for publication.
Publisher Copyright:
© 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
PY - 2021/8
Y1 - 2021/8
N2 - Background: Short dietary assessment tools can be useful to estimate food intake and diet quality in large-scale epidemiological studies with time constraints. Objective: To determine the concurrent validity of the 17-item energy-restricted Mediterranean Adherence Screener (er-MEDAS) used in the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial and to analyse its capacity to detect 1-year changes in diet and cardiometabolic risk factors. Methods: Validation study nested in the PREDIMED-Plus (n = 6760, 55–75 years). Dietary data were collected by the 17-item er-MEDAS and a 143-item validated semiquantitative food frequency questionnaire (FFQ) at baseline and after 1-year intervention. Cardiometabolic risk markers were measured at both time points. A Mediterranean diet (MedDiet) score was derived from both instruments. Concurrent validity was evaluated by Pearson and intra-class correlation coefficients (ICC) and Bland and Altman limits of agreement. Construct validity was evaluated by assessing 1-year changes in FFQ-reported dietary intake and cardiometabolic profile changes in relation to changes in er-MEDAS. Results: A moderate to good correlation between the MedDiet score calculated by both measurement instruments was found: r = 0.61 and ICC = 0.60 (both p < 0.001). Agreement of each of the er-MEDAS items ranged from 55.4% to 85.0% with a moderate mean concordance (kappa = 0.41). Between baseline and 1-year follow-up, energy intake measured by the FFQ decreased by 242 kcal, while Mediterranean food consumption increased in participants with the highest increase in the er-MEDAS MedDiet score. An increase in the er-MEDAS MedDiet score ratings was associated with a decrease in BMI, waist circumference, triglycerides, fasting glucose, diastolic blood pressure, and triglycerides/HDL-cholesterol ratio (p < 0.001 for all), and with an increase in HDL-cholesterol (p = 0.006). Conclusion: The er-MEDAS shows a modest to good concurrent validity compared with FFQ data. It shows acceptable construct validity, as a greater er-MEDAS score was associated with more favourable dietary and cardiometabolic profiles over time. Trial registry: ISRCTN89898870; registration date, 24 July 2014. https://www.isrctn.com/ISRCTN89898870.
AB - Background: Short dietary assessment tools can be useful to estimate food intake and diet quality in large-scale epidemiological studies with time constraints. Objective: To determine the concurrent validity of the 17-item energy-restricted Mediterranean Adherence Screener (er-MEDAS) used in the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial and to analyse its capacity to detect 1-year changes in diet and cardiometabolic risk factors. Methods: Validation study nested in the PREDIMED-Plus (n = 6760, 55–75 years). Dietary data were collected by the 17-item er-MEDAS and a 143-item validated semiquantitative food frequency questionnaire (FFQ) at baseline and after 1-year intervention. Cardiometabolic risk markers were measured at both time points. A Mediterranean diet (MedDiet) score was derived from both instruments. Concurrent validity was evaluated by Pearson and intra-class correlation coefficients (ICC) and Bland and Altman limits of agreement. Construct validity was evaluated by assessing 1-year changes in FFQ-reported dietary intake and cardiometabolic profile changes in relation to changes in er-MEDAS. Results: A moderate to good correlation between the MedDiet score calculated by both measurement instruments was found: r = 0.61 and ICC = 0.60 (both p < 0.001). Agreement of each of the er-MEDAS items ranged from 55.4% to 85.0% with a moderate mean concordance (kappa = 0.41). Between baseline and 1-year follow-up, energy intake measured by the FFQ decreased by 242 kcal, while Mediterranean food consumption increased in participants with the highest increase in the er-MEDAS MedDiet score. An increase in the er-MEDAS MedDiet score ratings was associated with a decrease in BMI, waist circumference, triglycerides, fasting glucose, diastolic blood pressure, and triglycerides/HDL-cholesterol ratio (p < 0.001 for all), and with an increase in HDL-cholesterol (p = 0.006). Conclusion: The er-MEDAS shows a modest to good concurrent validity compared with FFQ data. It shows acceptable construct validity, as a greater er-MEDAS score was associated with more favourable dietary and cardiometabolic profiles over time. Trial registry: ISRCTN89898870; registration date, 24 July 2014. https://www.isrctn.com/ISRCTN89898870.
KW - Diet
KW - Energy restriction
KW - Mediterranean diet
KW - Short screener
KW - Validation
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=85111833877&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2021.06.030
DO - 10.1016/j.clnu.2021.06.030
M3 - Article
C2 - 34364236
AN - SCOPUS:85111833877
SN - 0261-5614
VL - 40
SP - 4971
EP - 4979
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 8
ER -